A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa

Phase 3 Active not recruiting 565 enrolled Novartis Pharmaceuticals

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).

Timeline

Start: 2025-03-20
Primary completion: 2027-06-03
Completion: 2027-10-21

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Remibrutinib	Small molecule	—	Oral

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa

Summary

Timeline

Drugs

Indications